Article info

PDF

Extended report
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics

Authors

  1. Correspondence to Dr Thomas Frisell, Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm 17176, Sweden; thomas.frisell{at}ki.se
View Full Text

Citation

Frisell T, Baecklund E, Bengtsson K on behalf of the ARTIS Study group, et al
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics

Publication history

  • Received 15 September 2017
  • Revised 23 November 2017
  • Accepted 27 November 2017
  • Published online 13 December 2017.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.